Aims to accelerate development and commercialization of dry powder forms of niclosamide as a new potential treatment for COVID-19
Agreement provides for UNION therapeutics’ potential payment of development, regulatory and sales-related milestone payments of up to $210 million as well as tiered royalties
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.